)

Cue Biopharma (CUE) investor relations material
Cue Biopharma Cantor Global Healthcare Conference 2025 summary
Complete event summary combining all related documents: earnings call transcript, report, and slide presentation.
Recent clinical progress and data updates
- Initiated two phase III trials (VANQUISH-1 and VANQUISH-2) for VK2735 in obesity, with strong enrollment and operational progress. 
- Phase II oral VK2735 study showed clear dose response, strong efficacy at top dose, and good tolerability, though higher doses will not advance due to adverse events. 
- Maintenance study will test lower and higher oral doses, including daily and weekly regimens, to optimize long-term weight management. 
- Amylin analog program advancing toward pre-IND meeting, with potential for both standalone and combination therapy with VK2735. 
Market strategy and organizational development
- Company has doubled in size to over 50 employees, focusing on clinical operations and quality control to support large-scale trials. 
- Commercialization strategy may blend a smaller sales force with a strong online direct-to-patient presence, leveraging trends in the obesity market. 
- Maintenance market for obesity drugs seen as a major opportunity, with plans for monthly and low-dose oral formulations to support long-term adherence. 
- Cash-pay model for obesity drugs is expected to remain significant due to high demand and rapid market expansion. 
Regulatory and development outlook
- End-of-phase II meeting with FDA planned for oral VK2735, with potential for phase III initiation in the first half of next year depending on feedback. 
- Discontinuation rates in trials attributed mainly to adverse events and tablet fatigue; future studies will address tablet size and count. 
- Strategic interest in the obesity space remains high, with ongoing industry engagement and potential for future partnerships. 
- Non-invasive endpoints for NASH/MASH are not yet accepted by FDA, so no near-term plans for combo studies in this area, though external interest is increasing. 
Next Cue Biopharma earnings date

Next Cue Biopharma earnings date

The essential earnings season companion
The #1 app for live earnings calls, transcripts, analyst estimates, and more. All for free.
Live calls and transcripts
Listen to earnings calls, CMDs, investor conferences, and more – with a podcast-like experience.
Find what you need faster
Search for any keyword across all transcripts simultaneously.
Easily store key findings
Capturing important takeaways is as simple as it gets. Even during your lunch run or commute.
Your watchlist. Your dashboard.
Follow the companies that matter to you. Get a personalized feed with real-time updates.
Be the first to know
Set keyword alerts for any company, product, or competitor. Get notified the moment they're mentioned.
Consensus estimates
Access analyst consensus estimates, valuation multiples, and revenue segments splits.
All IR material in one place
The easiest way to stay updated during earnings season.
Global coverage
All events from public companies. Live and recorded.
Just click and listen
No webcast links. No manual registrations.
excellent app, it gives me free access to company earnings calls and annual reports. I also love the convenience of calls being available offline so I can listen in whilst doing other things and even when internet or WiFi isn't available.
)
One of the very few apps you could call perfect. If something was to add to it, maybe the share price of the company when you search for it, but it's already excellent.
)
This is genuinely one of the cleanest and fastest finance apps out there to track the market.
)
excellent app, it gives me free access to company earnings calls and annual reports. I also love the convenience of calls being available offline so I can listen in whilst doing other things and even when internet or WiFi isn't available.
)
One of the very few apps you could call perfect. If something was to add to it, maybe the share price of the company when you search for it, but it's already excellent.
)
This is genuinely one of the cleanest and fastest finance apps out there to track the market.
)
I can't remember the last time an app had such a positive impact on my investment process.
)
Love the app! Quartr makes it really easy to keep track of earnings calls. It also includes the reports and slides to make it easier to follow along.
)
Quartr is amazing, no way around it. It is the best right now for earnings calls, presentations, and the like.
)
I can't remember the last time an app had such a positive impact on my investment process.
)
Love the app! Quartr makes it really easy to keep track of earnings calls. It also includes the reports and slides to make it easier to follow along.
)
Quartr is amazing, no way around it. It is the best right now for earnings calls, presentations, and the like.
)
Frequently asked questions
- Mobile app: Research anytime, anywhere with the #1 app for live earnings calls, transcripts, analyst estimates, and more. All for free. 
- Desktop (Quartr Pro): The leading platform for qualitative research, used daily by top firms and financial institutions. 
- Quartr API: Build custom solutions powered by live earnings calls, live transcripts, filings and reports, slide presentations, and more. 
Explore our global coverage
)
)